Form D · Pharmaceuticals
Vivera Pharmaceuticals, Inc.
Newport Beach, CA · CIK 0001751371
Offering snapshot reported Sep 10, 2018 · SEC filing
- Reported sold
- $1.06M Offering amount: $3M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 24, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 10, 2018 | Initial | $1,055,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-320915
Source: Form D, filed Sep 10, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul Edalat | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
4533 Macarthur Boulevard #5049
Newport Beach, CA, 92660
Newport Beach, CA, 92660